Wockhardt Limited has received an upgraded ESG (Environmental, Social, and Governance) rating of 73 (Excellent) for 2025 from ESG Risk Assessments & Insights Limited, a SEBI-registered ESG rating provider. This represents a significant improvement from the company's previous ESG rating of 67.3 received for Financial Year 2024-25. The pharmaceutical company disclosed this latest information to stock exchanges on January 1, 2026, in compliance with regulatory requirements.

Latest ESG Rating Assessment

The new rating assignment was conducted voluntarily by ESG Risk Assessments & Insights Limited as part of their ESG assessment process. Similar to the previous rating, the company has clarified that it did not engage the rating provider for this purpose, making it an unsolicited assessment.

Rating Methodology and Independence

ESG Risk Assessments & Insights Limited determined the rating independently based on Wockhardt's public disclosures and other publicly available information. The rating provider conducted its assessment without any direct engagement or commissioning from the company, ensuring an objective evaluation of the pharmaceutical company's ESG practices and performance.

Regulatory Compliance and Disclosure

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. This regulatory framework mandates listed companies to inform exchanges about ESG ratings received from SEBI-registered providers.

The company has made this information available on its official website at www.wockhardt.com , ensuring transparency and accessibility for stakeholders. Company Secretary Rashmi Mamtura signed the regulatory filing dated January 1, 2026, with reference number WOCK/SEC/SE/2025-26/058, confirming the authenticity of the disclosure.

Wockhardt Limited has informed stock exchanges about receiving a GST demand order of ₹90.23 lakhs from tax authorities for the financial year 2019-20. The pharmaceutical company disclosed this development under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

GST Demand Order Details

The company received the tax demand order dated December 26, 2025, from the Superintendent, Central GST Range-11, Division-III, Ghaziabad. The total demand amount includes both the principal tax liability and penalties imposed by the authorities.

Nature of GST Violation

The demand has been raised due to adjustment of GST amount in the returns filed for FY 2019-20. According to the company's disclosure, the issue stems from excess GST paid during earlier years, which required adjustments in the subsequent financial year returns. The demand arose as part of the regular yearly assessment under current GST provisions.

Company's Response and Impact Assessment

Wockhardt Limited has expressed its disagreement with the demand order and announced plans to file an appropriate appeal against the tax authorities' decision. The company emphasized that this demand order will have no material impact on its financial position, operations, or other business activities.

The pharmaceutical company clarified that the GST demand emerged through routine assessment procedures and would not affect its ongoing operations. Management has assured stakeholders that necessary steps are being taken to contest the order through proper legal channels.

Regulatory Compliance and Disclosure

The company acknowledged a delay in making this disclosure to the stock exchanges, attributing it to an inadvertent administrative oversight. The disclosure was made upon realization of the omission, ensuring compliance with regulatory requirements.

Wockhardt Limited has confirmed that this intimation is also available on the company's official website at www.wockhardt.com , maintaining transparency with all stakeholders regarding this regulatory development.